Levetiracetam was first introduced in the US as an adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. This second-generation analog of piracetam can be prepared by condensation of (S)-2-aminobutyramide with 4-chlorobutyryl chloride. Although its mechanism of action is not well established, it was shown that [3H]-levetiracetam reversibly binds to a specific site predominantly present in the membranes of the brain.
| Product Name | Levetiracetam |
| CAS | 102767-28-2 |
| MF | C8H14N2O2 |
| EINECS | 600-348-9 |
| Melting point | 118-119°C |
| Storage conditions | 2-8°C |
1) Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures
2) Levetiracetam has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome.
3) It is also sometimes used to treat neuropathic pain.
4)It is suitable for the adjuvant treatment of adult epilepsy patients with partial or secondary generalized seizures.